Stefan W. Krause

Inhibitory effect of tumor cell–derived lactic acid on human T cells

Karin Fischer, Petra Hoffmann, Simon Voelkl et al. · Blood · 2007 · 1.8K citations · Full text

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

Oliver A. Cornely, Johan Maertens, Mark Bresnik et al. · Clinical Infectious Diseases · 2007 · 734 citations · Full text

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 582 citations · Full text

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al. · Leukemia · 2012 · 416 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Health Sciences +10

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9